Showing results (4141-4150 of 9,339) with videos related to

Sort By:
Pageof 934
Cancer Medicine|May 2, 2021
Comprehensive mutational analysis of background mucosa in patients with Lugol-voiding lesionsNaoki Akizue, Kenichiro Okimoto, Makoto Arai, et al.
Cancer Medicine|May 2, 2021
Associations between hepatitis B virus exposure and the risk of extrahepatic digestive system cancers: A hospital-based, case-control study (SIGES)Hui Wang, Xin-Zu Chen, Xiao-Long Chen, et al.
Cancer Medicine|May 3, 2021
First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous componentYu-Wen Zhou, Yi-Xiu Long, Ye Chen, et al.
Cancer Medicine|May 3, 2021
Recent improvement in survival outcomes and reappraisal of prognostic factors in hepatoblastomaKyung-Nam Koh, Jung-Man Namgoong, Hee Mang Yoon, et al.
Cancer Medicine|May 6, 2021
Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trialZhining Yang, Zeman Cai, Qingxin Cai, et al.
Cancer Medicine|May 6, 2021
Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancerGuodong Zhang, Qing Xu, Xiangyun Zhang, et al.
Cancer Medicine|May 8, 2021
Utility of liquid-based cytology on residual needle rinses collected from core needle biopsy for lung nodule diagnosisZhihua Lan, Xiaoli Zhang, Xin Ma, et al.
Cancer Medicine|June 12, 2020
Health-related quality of life in long-term prostate cancer survivors after nerve-sparing and non-nerve-sparing radical prostatectomy-Results from the multiregional PROCAS studySalome Adam, Eva Martin-Diener, Bertrand Camey, et al.
Cancer Medicine|June 4, 2020
The physiological characteristics of the basal microvilli microvessels in pancreatic cancersLixiang Ma, Xu Han, Jichun Gu, et al.
Cancer Medicine|June 4, 2020
Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysisPeng-Fei Zhang, Dan Xie, Feng Wen, et al.
Pageof 934